Participants in this study have been diagnosed with a type of bone cancer called chondrosarcoma that has spread to other parts of the body or is not able to be removed with surgery. In this study, all subjects will receive the drug pazopanib. This research study is being performed at about 5 clinics across the US. Approximately 47 subjects will take part in this study.
Mohammed Milhem, 319-356-2324
Heena Olalde, RN, MSN
Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
Participants in this research study have been diagnosed with multiple myeloma. This study is being done to see if the investigational drug (tabalumab) is safe and how well it works to help people with this particular cancer. Researchers also want to investigate how much tabalumab should be given and if tabalumab in combinsation with the drugs bortezomib and dexamethasone help people with myeloma. Researchers also want to investigate if the combination of drugs is safe and what side effects are associated with them.
Melanie Frees, 319-356-1228
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence
Participants in this research study have a type of cancer known as melanoma. This study is designed to help determine how safe the investigational vaccine POL-103A is and how it works in humans who have melanoma. This study will test two different doses of the POL-103A vaccine and one dose of placebo (an injection that will feel like the POL-103A injection but contains no vaccine). This is a blinded study. This means neither the participant or the study doctor will know if the participant is receiving the higher dose of the vaccine, the lower dose of vaccine, or the placebo dose. Study treatment can last as long as 24 months. With follow up continuing every 3 months.
Participants in this research study have been diagnosed with a type of multiple myeloma that has grown or spread and cannot be cured by surgery, radiation or any other conventional therapies. The purpose of this research study is to identify the side effects of the study drug, ALT-801, in patients with multiple myeloma, and to find out how safe it is, and how well it is tolerated. Investigators also wish to find out if the study drug can slow the progression of the disease and/or reduce the size of the tumors.
Karen Parrott, 319-353-6347
Copyright © 2013 The University of Iowa. All Rights Reserved.